ANI Pharmaceuticals

ANI PharmaceuticalsANI Pharmaceuticals
ANI Pharmaceuticals

ANI Pharmaceuticals

Diversified biopharmaceutical company focused on rare diseases, generics, and established brands.

DR 56Speed 681996Active707Baudette, United States
Rate

About

ANI Pharmaceuticals is a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics. Their strategic focus is on transforming into a leading Rare Disease company, while also maintaining a Generics and Established Brands business. They offer a range of prescription pharmaceutical products.
Frequently asked

What does ANI Pharmaceuticals do?

ANI Pharmaceuticals is a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics. Their strategic focus is on transforming into a leading Rare Disease company, while also maintaining a Generics and Established Brands business. They offer a range of prescription pharmaceutical products.

What is ANI Pharmaceuticals's revenue?

StartupHub estimates ANI Pharmaceuticals's annual revenue at $91.2M (range $50.3M to $169.1M, 66% confidence), based on comparable companies in the sector.

What is ANI Pharmaceuticals's valuation?

StartupHub estimates ANI Pharmaceuticals's effective valuation at $2.7B (range $1.7B to $4.0B, 14% confidence), based on comparable companies in the sector.

How much funding has ANI Pharmaceuticals raised?

ANI Pharmaceuticals has raised a total of $671M in funding. The most recent round on record is Acquisition.

Where is ANI Pharmaceuticals headquartered?

ANI Pharmaceuticals is headquartered in Baudette, United States.

When was ANI Pharmaceuticals founded?

ANI Pharmaceuticals was founded in 1996.

What industry does ANI Pharmaceuticals operate in?

ANI Pharmaceuticals operates in Biotech, Pharmaceuticals, Rare Disease, Generics, Drug Discovery, Manufacturing.

How many employees does ANI Pharmaceuticals have?

ANI Pharmaceuticals has approximately 707 people on record.

HEADCOUNT
707
DOMAIN RATING
56
Comments

No comments yet. Be the first to share your take.